Form 4: Tenaya Therapeutics Director, June Lee, Acquires 34,000 Stock Options

Director June Lee of Tenaya Therapeutics acquired 34,000 stock options on October 18, 2024, according to a recent SEC filing.

Summary

• June Lee, a director of Tenaya Therapeutics, Inc. (TNYA), acquired 34,000 stock options on October 18, 2024.
• The options have an exercise price of $2.04.
• The options were granted under the company's 2021 Equity Incentive Plan.
• The options will vest in full on May 31, 2025, or earlier if the next annual meeting of stockholders occurs before that date, contingent on continued service to the Issuer.
• Following the transaction, June Lee directly owns 34,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard transaction of stock options to a company director, aligning interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to align their interests with shareholders.
• The vesting schedule of these options is fairly standard, typically ranging from one to four years.
• The specific number of options granted and the exercise price would be benchmarked against similar companies in the biotech sector based on market capitalization and stage of development.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates